請用此 Handle URI 來引用此文件：
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/104642完整後設資料紀錄
| DC 欄位 | 值 | 語言 |
|---|---|---|
| dc.contributor.advisor | 黃敏銓 | zh_TW |
| dc.contributor.advisor | Min-Chuan Huang | en |
| dc.contributor.author | 李博謙 | zh_TW |
| dc.contributor.author | AMOS LEE PO QIAN | en |
| dc.date.accessioned | 2026-08-28T16:53:01Z | - |
| dc.date.available | 2026-08-29 | - |
| dc.date.copyright | 2026-08-28 | - |
| dc.date.issued | 2026 | - |
| dc.date.submitted | 2026-08-06 00:00:00 | - |
| dc.identifier.citation | 1. Cordero, R.J.B. and A. Casadevall, Melanin. Current Biology, 2020. 30(4): p. R142–R143.
2. Rzepka, Z., et al., From tyrosine to melanin: Signaling pathways and factors regulating melanogenesis. Postępy Higieny i Medycyny Doświadczalnej, 2016. 70: p. 695–708. 3. Snyman, M., et al., The metabolism of melanin synthesis-From melanocytes to melanoma. Pigment cell & melanoma research, 2024. 37. 4. Yamaguchi, Y. and V. Hearing, Melanocytes and Their Diseases. Cold Spring Harbor perspectives in medicine, 2014. 4. 5. Beyers, W.C., A.M. Detry, and S.M. Di Pietro, OCA7 is a melanosome membrane protein that defines pigmentation by regulating early stages of melanosome biogenesis. J Biol Chem, 2022. 298(12): p. 102669. 6. Kushimoto, T., et al., A model for melanosome biogenesis based on the purification and analysis of early melanosomes. Proc Natl Acad Sci U S A, 2001. 98(19): p. 10698–703. 7. Le, L., et al., Melanosome Biogenesis in the Pigmentation of Mammalian Skin. Integr Comp Biol, 2021. 61(4): p. 1517–1545. 8. Solano, F., On the Metal Cofactor in the Tyrosinase Family. Int J Mol Sci, 2018. 19(2). 9. Fernandez, P., et al., Study of tyrosine and dopa enantiomers as tyrosinase substrates initiating L‐ and D‐melanogenesis pathways. Biotechnology and Applied Biochemistry, 2020. 68. 10. Bertolotto, C., et al., Different cis-acting elements are involved in the regulation of TRP1 and TRP2 promoter activities by cyclic AMP: pivotal role of M boxes (GTCATGTGCT) and of microphthalmia. Mol Cell Biol, 1998. 18(2): p. 694–702. 11. Zolghadri, S., et al., Targeting tyrosinase in hyperpigmentation: Current status, limitations and future promises. Biochem Pharmacol, 2023. 212: p. 115574. 12. Zhou, S., et al., Epigenetic regulation of melanogenesis. Ageing Res Rev, 2021. 69: p. 101349. 13. Martina, J.A., et al., Novel roles for the MiTF/TFE family of transcription factors in organelle biogenesis, nutrient sensing, and energy homeostasis. Cell Mol Life Sci, 2014. 71(13): p. 2483–97. 14. Dall’Olmo, L., et al., Alpha-melanocyte stimulating hormone (α-MSH): biology, clinical relevance and implication in melanoma. Journal of Translational Medicine, 2023. 21. 15. Mayr, B. and M. Montminy, Mayr, B. & Montminy, M. R. Transcriptional regulation by the phosphorylation-dependent factor CREB. Nat. Rew. Mol. Cell Biol. 2, 599-609. Nature reviews. Molecular cell biology, 2001. 2: p. 599–609. 16. Kim, T., J.K. Kang, and C.G. Hyun, 6-Methylcoumarin Promotes Melanogenesis through the PKA/CREB, MAPK, AKT/PI3K, and GSK3β/β-Catenin Signaling Pathways. Molecules, 2023. 28(11). 17. Thapa, R., et al., A review of Glycogen Synthase Kinase-3 (GSK3) inhibitors for cancers therapies. International Journal of Biological Macromolecules, 2023. 253: p. 127375. 18. Gagliardi, P.A. and O. Pertz, The mitogen-activated protein kinase network, wired to dynamically function at multiple scales. Current Opinion in Cell Biology, 2024. 88: p. 102368. 19. Bellei, B., et al., p38 regulates pigmentation via proteasomal degradation of tyrosinase. J Biol Chem, 2010. 285(10): p. 7288–99. 20. Brown, D.A., Skin pigmentation enhancers. J Photochem Photobiol B, 2001. 63(1-3): p. 148–61. 21. Richani, D., et al., Participation of the adenosine salvage pathway and cyclic AMP modulation in oocyte energy metabolism. Sci Rep, 2019. 9(1): p. 18395. 22. Pang, M., et al., Molecular understanding of the therapeutic potential of melanin inhibiting natural products. RSC Med Chem, 2024. 15(7): p. 2226–2253. 23. Bao, M., M. Gempeler, and R. Campiche Melanosome Transport and Processing in Skin Pigmentation: Mechanisms and Targets for Pigmentation Modulation. International Journal of Molecular Sciences, 2025. 26, 8630 DOI: 10.3390/ijms26178630. 24. Merimsky, O., et al., Vitiligo- and melanoma-associated hypopigmentation: a similar appearance but a different mechanism. Cancer Immunol Immunother, 1994. 38(6): p. 411–6. 25. Saleem, M.D., et al., Acquired disorders with hypopigmentation: A clinical approach to diagnosis and treatment. Journal of the American Academy of Dermatology, 2019. 80(5): p. 1233–1250.e10. 26. Gholijani, N., et al., Emerging cell-based and cell-free therapeutic strategies for vitiligo. Journal of Translational Autoimmunity, 2025. 11: p. 100331. 27. Borderé, A.C., J. Lambert, and N. van Geel, Current and emerging therapy for the management of vitiligo. Clin Cosmet Investig Dermatol, 2009. 2: p. 15–25. 28. Cao, X., et al., Lactoferrin: A glycoprotein that plays an active role in human health. Frontiers in Nutrition, 2023. Volume 9 - 2022. 29. Ng, Z.J., et al., Lactoferrin in health and disease: A review of its bioavailability and evidence-based benefits across study models. Trends in Food Science & Technology, 2025. 160: p. 105024. 30. Ahmed, K., et al., Lactoferrin: potential functions, pharmacological insights, and therapeutic promises. Journal of Advanced Biotechnology and Experimental Therapeutics, 2021. 4: p. 223. 31. Rizzi, M., et al., Lactoferrin, a Natural Protein with Multiple Functions in Health and Disease. Nutrients, 2025. 17(21). 32. Hong, R., et al., A Review of the Biological Activities of Lactoferrin: Mechanisms and Potential Applications. Food & Function, 2024. 33. Zarzosa-Moreno, D., et al., Lactoferrin and Its Derived Peptides: An Alternative for Combating Virulence Mechanisms Developed by Pathogens. Molecules, 2020. 25(24). 34. Zong, X., et al., Role of lactoferrin and its derived peptides in metabolic syndrome treatment. Frontiers in Endocrinology, 2025. Volume 16 - 2025. 35. Zong, X., et al., Role of lactoferrin and its derived peptides in metabolic syndrome treatment. Front Endocrinol (Lausanne), 2025. 16: p. 1562653. 36. Hu, C., et al., Lactoferrin: Current situation and future prospects. Food Bioscience, 2024. 62: p. 105183. 37. Sun, J., et al., Research Progress on bioactive peptides from animal sources: A comprehensive review. Food Chemistry, 2025. 490: p. 145006. 38. Yu, B., et al., Research progress on peptides that inhibit melanin synthesis. Frontiers in Pharmacology, 2025. 16. 39. Orhan, I. and F. Senol Deniz, Inhibition of Melanogenesis by Some Well-Known Polyphenolics: A Review. Current Pharmaceutical Biotechnology, 2020. 21. 40. Fan, J., et al., Cell via Cell Viability Assay Changes Cellular Metabolic Characteristics by Intervening with Glycolysis and Pentose Phosphate Pathway. Chem Res Toxicol, 2024. 37(2): p. 208–211. 41. Park, J., et al., D-tyrosine negatively regulates melanin synthesis by competitively inhibiting tyrosinase activity. Pigment Cell Melanoma Res, 2018. 31(3): p. 374–383. 42. Abdelnour, S.A., et al., Therapeutic uses and applications of bovine lactoferrin in aquatic animal medicine: an overview. Vet Res Commun, 2023. 47(3): p. 1015–1029. 43. Kawakami, A. and D.E. Fisher, The master role of microphthalmia-associated transcription factor in melanocyte and melanoma biology. Lab Invest, 2017. 97(6): p. 649–656. 44. Lavoie, H., J. Gagnon, and M. Therrien, ERK signalling: a master regulator of cell behaviour, life and fate. Nat Rev Mol Cell Biol, 2020. 21(10): p. 607–632. 45. Wang, M., et al., JNK is constitutively active in mantle cell lymphoma: cell cycle deregulation and polyploidy by JNK inhibitor SP600125. J Pathol, 2009. 218(1): p. 95–103. 46. Huang, A., et al., LY294002 Is a Promising Inhibitor to Overcome Sorafenib Resistance in FLT3-ITD Mutant AML Cells by Interfering With PI3K/Akt Signaling Pathway. Front Oncol, 2021. 11: p. 782065. 47. Lochner, A. and J.A. Moolman, The many faces of H89: a review. Cardiovasc Drug Rev, 2006. 24(3-4): p. 261–74. 48. Konigsberg, W., [13] Reduction of disulfide bonds in proteins with dithiothreitol, in Methods in Enzymology. 1972, Academic Press. p. 185–188. 49. Konigsberg, W., [13] Reduction of disulfide bonds in proteins with dithiothreitol. Methods Enzymol, 1972. 25: p. 185–8. 50. Gao, R., et al., Cryptochrome 1 activation inhibits melanogenesis and melanosome transport through negative regulation of cAMP/PKA/CREB signaling pathway. Front Pharmacol, 2023. 14: p. 1081030. 51. Fosgerau, K. and T. Hoffmann, Peptide therapeutics: current status and future directions. Drug Discovery Today, 2015. 20(1): p. 122–128. 52. Wang, L., et al., Therapeutic peptides: current applications and future directions. Signal Transduction and Targeted Therapy, 2022. 7(1): p. 48. 53. Di, L., Strategic approaches to optimizing peptide ADME properties. Aaps j, 2015. 17(1): p. 134–43. 54. Liu, Y., Z. Zhao, and M. Li, Overcoming the cellular barriers and beyond: Recent progress on cell penetrating peptide modified nanomedicine in combating physiological and pathological barriers. Asian Journal of Pharmaceutical Sciences, 2022. 17(4): p. 523–543. 55. Guidotti, G., L. Brambilla, and D. Rossi, Cell-Penetrating Peptides: From Basic Research to Clinics. Trends in Pharmacological Sciences, 2017. 38(4): p. 406–424. 56. León-Calvijo, M.A., et al., Antibacterial activity of synthetic peptides derived from lactoferricin against Escherichia coli ATCC 25922 and Enterococcus faecalis ATCC 29212. Biomed Res Int, 2015. 2015: p. 453826. 57. Choi, J.Y., et al., Melanogenesis inhibitory compounds from Saussureae Radix. Arch Pharm Res, 2008. 31(3): p. 294–9. 58. Ward, P.S. and C.B. Thompson, Signaling in control of cell growth and metabolism. Cold Spring Harb Perspect Biol, 2012. 4(7): p. a006783. 59. Oka, M., et al., Regulation of melanogenesis through phosphatidylinositol 3-kinase-Akt pathway in human G361 melanoma cells. The Journal of investigative dermatology, 2000. 115(4): p. 699–703. 60. Slominski, A., et al., Melanin pigmentation in mammalian skin and its hormonal regulation. Physiol Rev, 2004. 84(4): p. 1155–228. 61. Manning, B.D. and A. Toker, AKT/PKB Signaling: Navigating the Network. Cell, 2017. 169(3): p. 381–405. 62. Zhou, K., et al., Mitochondrial deoxyguanosine kinase depletion induced ROS causes melanocyte stem cell exhaustion and hair greying. Cell Regen, 2025. 14(1): p. 25. 63. Buscà, R. and R. Ballotti, Cyclic AMP a key messenger in the regulation of skin pigmentation. Pigment Cell Res, 2000. 13(2): p. 60–9. 64. D'Mello, S.A., et al., Signaling Pathways in Melanogenesis. Int J Mol Sci, 2016. 17(7). 65. Yardman-Frank, J.M. and D.E. Fisher, Skin pigmentation and its control: From ultraviolet radiation to stem cells. Experimental Dermatology, 2021. 30(4): p. 560–571. 66. Snyman, M., et al., The metabolism of melanin synthesis-From melanocytes to melanoma. Pigment Cell Melanoma Res, 2024. 37(4): p. 438–452. 67. He, Y., et al., Targeting PI3K/Akt signal transduction for cancer therapy. Signal Transduction and Targeted Therapy, 2021. 6(1): p. 425. 68. Li, Q., E.N. Vlachos, and P. Bryant, Design of linear and cyclic peptide binders from protein sequence information. Communications Chemistry, 2025. 8(1): p. 211. 69. Wang, X.S., et al., A Genetically Encoded, Phage-Displayed Cyclic-Peptide Library. Angew Chem Int Ed Engl, 2019. 58(44): p. 15904–15909. 70. Chen, W., et al., Intramolecular disulfide bond between catalytic cysteines in an intein precursor. J Am Chem Soc, 2012. 134(5): p. 2500–3. 71. Kamentseva, R., et al., Functional cycle of EEA1-positive early endosome: Direct evidence for pre-existing compartment of degradative pathway. PLOS ONE, 2020. 15(5): p. e0232532. 72. Shearer, L.J. and N.O. Petersen, Distribution and Co-localization of endosome markers in cells. Heliyon, 2019. 5(9): p. e02375. 73. Huotari, J. and A. Helenius, Endosome maturation. Embo j, 2011. 30(17): p. 3481–500. 74. Humphries, W.H.t., C.J. Szymanski, and C.K. Payne, Endo-lysosomal vesicles positive for Rab7 and LAMP1 are terminal vesicles for the transport of dextran. PLoS One, 2011. 6(10): p. e26626. 75. Scott, C.C., F. Vacca, and J. Gruenberg, Endosome maturation, transport and functions. Seminars in Cell & Developmental Biology, 2014. 31: p. 2–10. 76. Rarokar, N., et al., Chapter 1 - Phototherapy: A critical review, in Photophysics and Nanophysics in Therapeutics, N.M. Mahajan, et al., Editors. 2022, Elsevier. p. 3–14. 77. Gruden, Š., et al. Lactoferrin and Its Enzymatic Hydrolysates as Natural Antimicrobial and Antioxidant Agents for Food Preservation. Foods, 2026. 15, 1052 DOI: 10.3390/foods15061052. 78. Huang, H.C., H. Lin, and M.C. Huang, Lactoferrin promotes hair growth in mice and increases dermal papilla cell proliferation through Erk/Akt and Wnt signaling pathways. Arch Dermatol Res, 2019. 311(5): p. 411–420. 79. Dyrda-Terniuk, T. and P. Pomastowski, The Multifaceted Roles of Bovine Lactoferrin: Molecular Structure, Isolation Methods, Analytical Characteristics, and Biological Properties. Journal of Agricultural and Food Chemistry, 2023. 71(51): p. 20500–20531. 80. Yan, D., et al., Bovine lactoferricin is anti-inflammatory and anti-catabolic in human articular cartilage and synovium. J Cell Physiol, 2013. 228(2): p. 447–56. 81. Arias, M., et al., Bovine and human lactoferricin peptides: chimeras and new cyclic analogs. Biometals, 2014. 27(5): p. 935–48. 82. Li, X., et al., Enzyme purification and sustained enzyme activity for pharmaceutical biocatalysis by fusion with phase-separating intrinsically disordered protein. Biotechnology and Bioengineering, 2024. 121(10): p. 3155–3168. 83. Liu, B., et al., A biomimetic multifunctional dressing based on stratum corneum microstructure: integrating antibacterial barrier and breathability for enhanced wound healing. Biomaterials, 2026. 326: p. 123639. | - |
| dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/104642 | - |
| dc.description.abstract | 黑色素在皮膚與毛髮中扮演著抵禦紫外線 (UV) 傷害及維持外觀的重要角色。黑色素生成過程受到細胞內複雜訊息路徑的調控，並依賴黑色素體的成熟與酪氨酸酶等關鍵酵素的活化。當機制發生失調時，便會引發黑色素缺失疾病，如白斑症與早發性灰白髮，仍是目前臨床皮膚科學面臨的重要挑戰。由於現有臨床促黑治療常面臨療效有限與高復發率的瓶頸，且傳統方式如類固醇治療亦導致皮膚萎縮、微血管擴張、甚至誘發毛囊炎。近年來，乳鐵蛋白展現出豐富的生物活性，其衍生胜肽更因具備高專一性與優異的生物相容性，成為新興藥物開發的熱點；然而，其在調控黑色素生成中的作用與機制尚不完全清楚。在本研究中，我們透過篩選乳鐵蛋白衍生胜肽庫，發現 bLF1 (CVRRAFVLEC) 能顯著促進 B16F10 細胞的黑色素合成，且在長達 72 小時與高達 200 µg/mL 的高濃度處理下，依然維持極佳的細胞存活率。在分子機制上，bLF1在不影響細胞活性的情況下，透過標靶活化 PKA/CREB 訊息傳遞軸驅動下游酵素表現，上調了MITF，TYR，TRP1 等黑色素促進相關的蛋白表現量。此外，形成分子內雙硫鍵的 10-mer 環狀結構，能顯著強化其促黑能力；免疫熒光染色追蹤也發現，bLF1 能透過內吞作用進入並穩定累積於晚期內體中以發揮效應。
綜上所述，本研究確立了 bLF1 為一款高效且無毒性的多功能候選胜肽，有望為未來黑色素缺失疾病提供具臨床價值的潛力藥物。 | zh_TW |
| dc.description.abstract | Melanin plays a crucial role in the skin and hair by protecting against ultraviolet (UV) damage and maintaining physical appearance. Melanogenesis is regulated by different intracellular signaling pathways and relies on melanosome maturation and the activation of key enzymes. Dysregulation of this mechanism leads to hypopigmentation disorders, such as vitiligo and premature hair graying, which remain significant challenges in clinical dermatology. Current clinical therapies are often hindered by limited efficacy and high recurrence rates. Furthermore, traditional treatments like corticosteroids can cause adverse effects, including skin atrophy, telangiectasia, and even folliculitis. Recently, lactoferrin has exhibited diverse bioactivities, and its derived peptides have emerged for novel drug development due to their high specificity and superior biocompatibility; however, their roles and mechanisms in regulating melanogenesis remain unclear. In this study, by screening a library of lactoferrin-derived peptides, we discovered that bLF1 (CVRRAFVLEC) significantly promotes melanin synthesis in B16F10 cells while maintaining exceptional cell viability, even under long-term (72 hours) and high-concentration (200 µg/mL) treatments. The underlying mechanism is that bLF1 activates the PKA/CREB signaling axis to drive downstream enzyme expression, thereby upregulating key melanogenic proteins such as MITF, TYR, and TRP1. Furthermore, the 10-mer cyclic structure formed by an intramolecular disulfide bond significantly enhances its melanogenic capacity. Immunofluorescence tracking also revealed that bLF1 is internalized via endocytosis and stably accumulates in late endosomes to exert its downstream effects.
In conclusion, this study establishes bLF1 as a highly efficient and non-toxic multifunctional candidate peptide, offering a promising therapeutic option with significant clinical value for the future treatment of hypopigmentation disorders. | en |
| dc.description.provenance | Submitted by admin ntu (admin@lib.ntu.edu.tw) on 2026-08-28T16:53:01Z No. of bitstreams: 0 | en |
| dc.description.provenance | Made available in DSpace on 2026-08-28T16:53:01Z (GMT). No. of bitstreams: 0 | en |
| dc.description.tableofcontents | CONTENTS
口試委員會審定書 # 誌謝 ii 中文摘要 iii ABSTRACT iv CONTENTS vi LIST OF FIGURES ix Chapter 1 Introduction 1 1.1 Physiological Role of Melanin 1 1.2 Melanosome Biogenesis and Maturation 1 1.3 Key Melanogenic Enzymes 2 1.4 Signaling Pathways in Melanogenesis 3 1.5 Clinical Challenges of Hypopigmentation 5 1.6 Bioactivities of Lactoferrin 6 1.7 Potential of Lactoferrin-Derived Peptides 7 1.8 Specific Aims 8 1.8.1 To identify novel lactoferrin-derived peptides that promote melanogenesis. 8 1.8.2 To evaluate the cellular efficacy of target lactoferrin-derived peptides. 8 1.8.3 To elucidate the molecular mechanism and structural prerequisite driving peptide-induced melanogenesis. 8 Chapter 2 Methods and Materials 9 2.1 Reagents and Antibodies 9 2.2 Cell Culture 10 2.3 Peptide Synthesis and Preparation 11 2.4 Cell Viability Assay 12 2.5 Melanin Content Assay 12 2.6 Tyrosinase Activity Assay 13 2.7 L-DOPA Staining Assay 13 2.8 DPPH Assay 14 2.9 Nitric Oxide Production Assay 15 2.10 Western Blotting 15 2.11 High-Resolution Mass Spectrometry 16 2.12 Immunofluorescence Confocal Microscopy 17 2.13 Statistical Analysis 17 Chapter 3 Result 18 3.1 Screening of bovine lactoferrin-derived peptides for melanogenic activity in B16F10 cells 18 3.2 bLF1 significantly induces melanin synthesis in B16F10 cells 18 3.3 Dose-dependent melanogenic effects and cytotoxicity evaluation of bLF1 19 3.4 bLF1 enhances intracellular tyrosinase activity 20 3.5 Evaluation of the antioxidant and anti-inflammatory properties of bLF1 20 3.6 Evaluation of MITF expression and upstream regulatory proteins following bLF1 treatment 21 3.7 bLF1-induced melanogenesis is independent of the JNK, p38, and AKT signaling pathways 22 3.8 bLF1 upregulates melanogenesis via the PKA/CREB signaling pathway 23 3.9 Disulfide bond formation and sequence integrity are essential for the melanogenic activity of bLF1 24 3.10 Intracellular localization of bLF1 and the proposed working model 25 Chapter 4 Discussion 27 4.1 Summary 27 4.2 Biocompatibility of bLF1 in Melanogenesis 27 4.3 Activation of the PKA/CREB Signaling Axis by bLF1 29 4.4 Structural Prerequisites of bLF1 30 4.5 Cellular Uptake and Subcellular Localization of bLF1 31 4.6 Clinical Implications and Future Perspectives 33 REFERENCE 36 LIST OF FIGURES Figure 1. Sequence and schematic generation of lactoferrin-derived candidate peptides. 41 Figure 2. Primary screening of lactoferrin-derived peptides for melanogenesis induction. 42 Figure 3. Validation of melanogenesis induction by selected candidate peptides. 43 Figure 4. Melanogenic efficacy and cytotoxicity assessment of bLF1 in B16F10 cells. 44 Figure 5. Microscopic observation of melanin synthesis and tyrosinase activity in B16F10 cells treated with bLF1. 45 Figure 6. Evaluation of the antioxidant and anti-inflammatory activities of lactoferrin-derived peptides. 46 Figure 7. Signaling pathways involved in bLF1-induced melanogenesis in B16F10 cells. 47 Figure 8. Role of JNK and p38 MAPK pathways in bLF1-induced melanogenesis. 48 Figure 9. Role of the AKT signaling pathway in bLF1-induced melanogenesis. 49 Figure 10. Role of the PKA signaling pathway in bLF1-induced melanogenesis. 50 Figure 11. bLF1 upregulates melanogenic proteins via the PKA/CREB signaling pathway. 51 Figure 12. The intramolecular disulfide bond is essential for bLF1-induced melanogenesis. 51 Figure 13. Truncation of bLF1 to a linear 9-mer significantly reduces its melanogenic activity. 53 Figure 14. Biotinylation preserves bLF1 melanogenic activity and reveals its subcellular localization. 54 Figure 15. Proposed mechanism of bLF1-induced melanogenesis in B16F10 cells. 55 | - |
| dc.language.iso | zh_TW | - |
| dc.subject | 黑色素生成、乳鐵蛋白衍生胜肽、PKA/CREB 訊息傳遞路徑、生物相容性、黑色素缺失疾病 | - |
| dc.subject | Melanogenesis, Lactoferrin-derived peptide, PKA/CREB signaling pathway, Biocompatibility, Hypopigmentation disorders | - |
| dc.title | 乳鐵蛋白衍生胜肽調節黑色素生成之篩選與功能探討 | zh_TW |
| dc.title | Screening and Functional Characterization of Lactoferrin-Derived Peptides in Melanogenesis | en |
| dc.type | Thesis | - |
| dc.date.schoolyear | 114-2 | - |
| dc.description.degree | 碩士 | - |
| dc.contributor.oralexamcommittee | 林能裕;余兆武 | zh_TW |
| dc.contributor.oralexamcommittee | Neng-Yu Lin;CHAO-WU YU | en |
| dc.subject.keyword | 黑色素生成、乳鐵蛋白衍生胜肽、PKA/CREB 訊息傳遞路徑、生物相容性、黑色素缺失疾病 | zh_TW |
| dc.subject.keyword | Melanogenesis, Lactoferrin-derived peptide, PKA/CREB signaling pathway, Biocompatibility, Hypopigmentation disorders | en |
| dc.relation.page | 55 | - |
| dc.identifier.doi | 10.6342/NTU202603434 | - |
| dc.rights.note | 同意授權(全球公開) | - |
| dc.date.accepted | 2026-08-06 | - |
| dc.contributor.author-college | 醫學院 | - |
| dc.contributor.author-dept | 解剖學暨細胞生物學研究所 | - |
| dc.date.embargo-lift | 2026-08-29 | - |
| 顯示於系所單位： | 解剖學暨細胞生物學科所 | |
文件中的檔案：
| 檔案 | 大小 | 格式 | |
|---|---|---|---|
| ntu-114-2.pdf | 2.91 MB | Adobe PDF | 檢視/開啟 |
系統中的文件，除了特別指名其著作權條款之外，均受到著作權保護，並且保留所有的權利。